Haruki Shibata

Haruki Shibata is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of dyslipidemic conditions. With a total of 5 patents to his name, Shibata's work is recognized for its innovative approaches to drug composition and therapeutic agents.

Latest Patents

One of Shibata's latest patents is focused on a dyslipidemia therapeutic agent. This invention provides a combination-drug composition aimed at preventing and treating dyslipidemic conditions, such as hyper-LDL cholesterolemia, in mammals, including humans. The drug composition includes specific compounds that have shown efficacy in addressing these health issues. Another notable patent involves substituted pyrimidine compounds, which serve as cholesterol ester transfer protein (CETP) inhibitors. These compounds are characterized by their potent inhibitory activity, making them valuable in the management of cholesterol levels.

Career Highlights

Haruki Shibata is associated with Kowa Company Limited, where he continues to advance research in pharmaceutical innovations. His work has been instrumental in developing new therapeutic options for patients suffering from dyslipidemia. Shibata's dedication to improving health outcomes through innovative drug formulations is evident in his patent portfolio.

Collaborations

Shibata has collaborated with notable colleagues, including Tadaaki Ohgiya and Toru Miura. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

Haruki Shibata's contributions to the field of pharmaceuticals, particularly in dyslipidemia treatment, highlight his role as an influential inventor. His innovative patents and collaborations reflect a commitment to advancing medical science and improving patient care.

This text is generated by artificial intelligence and may not be accurate.